IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Stancheva, Gergana ^a   Goranova, Teodora ^a   Laleva, Maria ^b   Kamenova, Margarita ^b   Mitkova, Atanaska ^a   Velinov, Nikolay ^b   Poptodorov, George ^b   Mitev, Vanio ^a   Kaneva, Radka ^a   Gabrovsky, Nikolay ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Pirogov Multiprofile Hospital for Activ Treatment and Emergency Medicine   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN P53; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BULGARIA; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC DISORDER; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREVALENCE; SURVIVAL TIME; BRAIN NEOPLASMS; CHROMOSOME ABERRATION; DNA SEQUENCE; GENETICS; HOMOZYGOTE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; BULGARIA; CHROMOSOME ABERRATIONS; FEMALE; GENES, P53; GLIOBLASTOMA; HOMOZYGOTE; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901272598     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/654727     Document Type: Article

References (46)

1. Wager M., Menei P., Guilhot J., Levillain P., Michalak S., Bataille B., Blanc J., Lapierre F., Rigoard P., Milin S., Duthe F., Bonneau D., Larsen C., Karayan-Tapon K., Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. The British Journal of Cancer 2008 98 11 1830 1838 2-s2.0-44349136238 10.1038/sj.bjc.6604378 (Pubitemid 351748843)
2. Furnari F. B., Fenton T., Bachoo R. M., Mukasa A., Stommel J. M., Stegh A., Hahn W. C., Ligon K. L., Louis D. N., Brennan C., Chin L., DePinho R. A., Cavenee W. K., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development 2007 21 21 2683 2710 2-s2.0-35949002429 10.1101/gad.1596707 (Pubitemid 350070717)
3. TCGA, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 455 7216 1061 1068 10.1038/nature07385
4. Ducray F., Hallani S. E., Idbaih A., Diagnostic and prognostic markers in gliomas. Current Opinion in Oncology 2009 21 6 537 542 2-s2.0-74049107766 10.1097/CCO.0b013e32833065a7
5. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J. P., Heese O., Reifenberger G., Weller M., Schackert G., Long-term survival with glioblastoma multiforme. Brain 2007 130 10 2596 2606 2-s2.0-34848824363 10.1093/brain/awm204 (Pubitemid 47511715)
6. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J. P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J. C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., Von Deimling A., Loeffler M., Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network. Journal of Clinical Oncology 2009 27 34 5743 5750 2-s2.0-73349103157 10.1200/JCO.2009.23.0805
7. Parsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A. Jr., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K. N., Shinjo S. M. O., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W., An integrated genomic analysis of human glioblastoma multiforme. Science 2008 321 5897 1807 1812 2-s2.0-52949127312 10.1126/science.1164382
8. Kloosterhof N. K., Bralten L. B., Dubbink H. J., French P. J., van den Bent M. J., Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? The Lancet Oncology 2011 12 1 83 91 2-s2.0-78650682939 10.1016/S1470-2045(10)70053-X
9. Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., Ding J., Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. The Journal of Biological Chemistry 2004 279 32 33946 33957 2-s2.0-4043105583 10.1074/jbc.M404298200 (Pubitemid 39063045)
10. Yang B., Zhong C., Peng Y., Lai Z., Ding J., Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H. Cell Research 2010 20 11 1188 1200 2-s2.0-78049480082 10.1038/cr.2010.145
11. Bleeker F. E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W. P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A., Bardelli A., IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation 2009 30 1 7 11 2-s2.0-58349111311 10.1002/humu.20937
12. Dang L., Jin S., Su S. M., IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine 2010 16 9 392 397 2-s2.0-77956265489 10.1016/j.molmed.2010.07.002
13. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A., Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008 116 6 597 602 2-s2.0-56749156414 10.1007/s00401-008-0455-2
14. Ichimura K., Pearson D. M., Kocialkowski S., Bäcklund L. M., Chan R., Jones D. T. W., Collins V. P., IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 2009 11 4 341 347 2-s2.0-68349116524 10.1215/15228517-2009-025
15. Toedt G., Barbus S., Wolter M., Felsberg J., Tews B., Blond F., Sabel M. C., Hofmann S., Becker N., Hartmann C., Ohgaki H., von Deimling A., Wiestler O. D., Hahn M., Lichter P., Reifenberger G., Radlwimmer B., Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer 2011 128 5 1095 1103 2-s2.0-78650749129 10.1002/ijc.25448
16. von Deimling A., Korshunov A., Hartmann C., The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathology 2011 21 1 74 87 2-s2.0-78650018623 10.1111/j.1750-3639.2010.00454.x
17. Yan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G. J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K. W., Velculescu V. E., Vogelstein B., Bigner D. D., IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009 360 8 765 773 2-s2.0-60849115270 10.1056/NEJMoa0808710
18. Dubbink H. J., Taal W., van Marion R., Kros J. M., van Heuvel I., Bromberg J. E., Zonnenberg B. A., Zonnenberg C. B. L., Postma T. J., Gijtenbeek J. M. M., Boogerd W., Groenendijk F. H., Smitt P. A. E. S., Dinjens W. N. M., van den Bent M. J., IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009 73 21 1792 1795 2-s2.0-73349108806 10.1212/WNL.0b013e3181c34ace
19. Riemenschneider M. J., Jeuken J. W. M., Wesseling P., Reifenberger G., Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica 2010 120 5 567 584 2-s2.0-78149405879 10.1007/s00401-010-0736-4
20. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., Hallani S. E., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology 2009 27 25 4150 4154 2-s2.0-70249097408 10.1200/JCO.2009.21.9832
21. Butowski N. A., Chang S. M., Glial tumors: the current state of scientific knowledge. Clinical Neurosurgery 2006 53 106 113 2-s2.0-34248560872
22. Soussi T., Wiman K. G., Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007 12 4 303 312 2-s2.0-35148826938 10.1016/j.ccr.2007.10.001 (Pubitemid 47539312)
23. Ohgaki H., Kleihues P., Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science 2009 100 12 2235 2241 2-s2.0-70449711757 10.1111/j.1349-7006.2009.01308.x
24. Hill J. R., Kuriyama N., Kuriyama H., Israel M. A., Molecular genetics of brain tumors. Archives of Neurology 1999 56 4 439 441 2-s2.0-0032919618 (Pubitemid 29166337)
25. Tabatabai G., Stupp R., Van Den Bent M. J., Hegi M. E., Tonn J. C., Wick W., Weller M., Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica 2010 120 5 585 592 2-s2.0-78149388926 10.1007/s00401-010-0750-6
26. Ohgaki H., Kleihues P., Genetic pathways to primary and secondary glioblastoma. The American Journal of Pathology 2007 170 5 1445 1453 2-s2.0-34250877865 10.2353/ajpath.2007.070011 (Pubitemid 47339290)
27. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W., Kleihues P., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007 114 2 97 109 2-s2.0-34547122001 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
28. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J. W. M., Wesseling P., Reifenberger G., von Deimling A., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 2009 118 4 469 474 2-s2.0-69949114447 10.1007/s00401-009-0561- 9
29. van den Bent M. J., Dubbink H. J., Marie Y., Brandes A. A., Taphoorn M. J. B., Wesseling P., Frenay M., Tijssen C. C., Lacombe D., Idbaih A., van Marion R., Kros J. M., Dinjens W. N. M., Gorlia T., Sanson M., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clinical Cancer Research 2010 16 5 1597 1604 2-s2.0-77649122144 10.1158/1078-0432.CCR-09-2902
30. Zhao S., Lin Y., Xu W., Jiang W., Zhai Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K., Xiong Y., Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α Science 2009 324 5924 261 265 2-s2.0-64849098267 10.1126/science.1170944
31. Dang L., White D. W., Gross S., Bennett B. D., Bittinger M. A., Driggers E. M., Fantin V. R., Jang H. G., Jin S., Keenan M. C., Marks K. M., Prins R. M., Ward P. S., Yen K. E., Liau L. M., Rabinowitz J. D., Cantley L. C., Thompson C. B., Vander Heiden M. G., Su S. M., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 462 7274 739 744 2-s2.0-72049125350 10.1038/nature08617
32. Lu C., Ward P. S., Kapoor G. S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C. R., Khanin R., Figueroa M. E., Melnick A., Wellen K. E., Oĝrourke D. M., Berger S. L., Chan T. A., Levine R. L., Mellinghoff I. K., Thompson C. B., IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483 7390 474 478 2-s2.0-84858796262 10.1038/nature10860
33. Noushmehr H., Weisenberger D. J., Diefes K., Phillips H. S., Pujara K., Berman B. P., Pan F., Pelloski C. E., Sulman E. P., Bhat K. P., Verhaak R. G. W., Hoadley K. A., Hayes D. N., Perou C. M., Schmidt H. K., Ding L., Wilson R. K., van den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L. M., Buckley J., Herman J. G., Baylin S. B., Laird P. W., Aldape K., Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010 17 5 510 522 2-s2.0-77952108366 10.1016/j.ccr.2010.03.017
34. Turcan S., Rohle D., Goenka A., Walsh L. A., Fang F., Yilmaz E., Campos C., Fabius A. W. M., Lu C., Ward P. S., Thompson C. B., Kaufman A., Guryanova O., Levine R., Heguy A., Viale A., Morris L. G. T., Huse J. T., Mellinghoff I. K., Chan T. A., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 483 7390 479 483 2-s2.0-84858796263 10.1038/nature10866
35. Jin G., Reitman Z. J., Duncan C. G., Spasojevic I., Gooden D. M., Rasheed B. A., Yang R., Lopez G. Y., He Y., McLendon R. E., Bigner D. D., Yan H., Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research 2013 73 2 496 501 10.1158/0008-5472.CAN- 12-2852
36. Gupta R., Flanagan S., Li C. C., Lee M., Shivalingham B., Maleki S., Wheeler H. R., Buckland M. E., Expanding the spectrum of IDH1 mutations in gliomas. Modern Pathology 2013 26 5 619 625 10.1038/modpathol.2012.210
37. Zhang Y., Wei H., Wang M., Huai L., Mi Y., Zhang Y., Lin D., Liu B., Li W., Zhou C., Rao Q., Wang J., Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leukemia Research 2011 35 10 1301 1306 2-s2.0-80052085638 10.1016/j.leukres.2011.01.019
38. Murugan A. K., Bojdani E., Xing M., Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications 2010 393 3 555 559 2-s2.0-77949262337 10.1016/j.bbrc.2010.02.095
39. +-dependent isocitrate dehydrogenase mutations. PLoS ONE 2011 6 2 2-s2.0-79951542753 10.1371/journal.pone.0016812 e16812
40. Ward P. S., Patel J., Wise D. R., Abdel-Wahab O., Bennett B. D., Coller H. A., Cross J. R., Fantin V. R., Hedvat C. V., Perl A. E., Rabinowitz J. D., Carroll M., Su S. M., Sharp K. A., Levine R. L., Thompson C. B., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α -ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010 17 3 225 234 2-s2.0-77649305610 10.1016/j.ccr.2010.01.020
41. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T., Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science 2009 100 10 1996 1998 2-s2.0-70349594347 10.1111/j.1349-7006.2009.01270.x
42. Takano S., Kato Y., Yamamoto T., Kaneko M. K., Ishikawa E., Tsujimoto Y., Matsuda M., Nakai K., Yanagiya R., Morita S., Tsuboi K., Matsumura A., Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Journal of Neuro-Oncology 2012 108 3 361 373 2-s2.0-84857681917 10.1007/s11060-012-0837-0
43. +-dependent IDH activity in glioblastoma. Acta Neuropathologica 2010 119 4 487 494 2-s2.0-77953019788 10.1007/s00401-010-0645-6
44. Hemerly J. P., Bastos A. U., Cerutti J. M., Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. European Journal of Endocrinology 2010 163 5 747 755 2-s2.0-77957835307 10.1530/EJE-10-0473
45. Wagner K., Damm F., Göhring G., Görlich K., Heuser M., Schäfer I., Ottmann O., Lübbert M., Heit W., Kanz L., Schlimok G., Raghavachar A. A., Fiedler W., Kirchner H. H., Brugger W., Zucknick M., Schlegelberger B., Heil G., Ganser A., Krauter J., Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Journal of Clinical Oncology 2010 28 14 2356 2364 2-s2.0-77952481300 10.1200/JCO.2009.27. 6899
46. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., Westphal M., Schackert G., Meyermann R., Pietsch T., Reifenberger G., Weller M., Loeffler M., von Deimling A., Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica 2010 120 6 707 718 2-s2.0-78651082266 10.1007/s00401-010-0781-z